Nasal Foralumab for the Treatment of Progression Independent of Relapses in Patients With Nonactive Secondary Progressive Multiple Sclerosis
Progression independent of relapses (PIRA) is a major therapeutic challenge in multiple sclerosis (MS). Nasal anti-CD3 treats animal models of progressive MS by inducing regulatory T cells (Tregs) that suppress CNS inflammation and lessen clinical disease.
Authors
- Taylor J. Saraceno (ORCID: https://orcid.org/0000-0002-2605-8505)
- Regan W. Bergmark (ORCID: https://orcid.org/0000-0003-3249-4343)
- Jessica Ye (ORCID: https://orcid.org/0000-0001-8392-7423)
- Shrishti Saxena (ORCID: https://orcid.org/0000-0003-3429-5671)
- Brenna A. LaBarre
- D. A. King (ORCID: https://orcid.org/0000-0002-5784-8534)
- Steven Cicero
- Moogeh Baharnoori
- Jonathan Zurawski (ORCID: https://orcid.org/0000-0002-2896-8369)
- William A. Clementi
- Alice Z. Maxfield (ORCID: https://orcid.org/0000-0003-2608-2094)
- Evan Madill (ORCID: https://orcid.org/0009-0006-5482-1949)
- Steven Vaquerano
- Hong Pan (ORCID: https://orcid.org/0000-0002-8124-8184)
- Nancy Clementi
- Manali Shah Sheth (ORCID: https://orcid.org/0000-0002-6588-3663)
- B.F Healy
- Caleb Hansel
- Tanuja Chitnis
- Tarun Singhal
- Lauren Cain
- Howard L. Weiner
- Rachel Rodin
- Shipra Dubey
- Niveditha Gopalakrishnan
- Hrishikesh A. Lokhande
Institutions
- Bryn Mawr College (US)
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Bryn Mawr Hospital (US)
- Fundação Bahiana de Infectologia (BR)
Publication Details
- Journal
- Neurology Neuroimmunology & Neuroinflammation
- Published
- 2026-01-16
- DOI
- https://doi.org/10.1212/nxi.0000000000200543
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Defense
- Bristol-Myers Squibb
- Sanofi
- BrightFocus Foundation
- F. Hoffmann-La Roche
- Merck KGaA
- Massachusetts Life Sciences Center
- Race to Erase MS
- Multiple Sclerosis Society
- National Institutes of Health
- Genentech
- EMD Serono
- Sanofi Genzyme